Company
SINOVAC at Glance
Our History
Social Responsibilities
Innovation
R&D Platform
Pipeline
Scientific Achievements
Partners
— Research Institute
— Universities
— Medical Institutions
— Companies
Products
Vaccines
International Business
Quality Management System
Product Consultation
Adverse Event Report
News
Press Releases
Updates and Statements
Media Asset Library
Investors
Corporate Governance
Financial Reports
SEC Filings
Careers
Our Talent
中文
EN
Contact Us
Company
SINOVAC at Glance
Our History
Social Responsibilities
News
Press Releases
Updates and Statements
Media Asset Library
— Logo
— Vaccines
Innovation
R&D Platform
Pipeline
Scientific Achievements
Partners
— Research Institute
— Universities
— Medical Institutions
— Companies
Products
Vaccines
International Business
Quality Management System
Product Consultation
Adverse Event Report
Investors
Corporate Governance
— Board of Directors
— Management
Financial Reports
— YEAR 2022
— YEAR 2021
— YEAR 2020
— YEAR 2019
— YEAR 2018
— YEAR 2017
— YEAR 2016
— YEAR 2015
— YEAR 2014
— YEAR 2013
— YEAR 2012
— YEAR 2011
— YEAR 2010
— YEAR 2009
— YEAR 2008
— YEAR 2007
— YEAR 2006
— YEAR 2005
— YEAR 2004
— YEAR 2003
SEC Filings
— YEAR 2023
— YEAR 2022
— YEAR 2021
— YEAR 2020
— YEAR 2019
— YEAR 2018
— YEAR 2017
— YEAR 2016
— YEAR 2015
— YEAR 2014
— YEAR 2013
— YEAR 2012
— YEAR 2011
— YEAR 2010
— YEAR 2009
Careers
Our Talent
Contact Us
联系我们
当前地点：
EN
选择地点：
中文
EN
Home
Company
SINOVAC at Glance
Our History
Social Responsibilities
News
Press Releases
Updates and Statements
Media Asset Library
Innovation
R&D Platform
Pipeline
Scientific Achievements
Partners
Products
Vaccines
International Business
Quality Management System
Product Consultation
Adverse Event Report
Investors
Corporate Governance
Financial Reports
SEC Filings
Careers
Our Talent
Contact Us
中文
EN
SEC Filings
Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer
2023-09-05 17:40:15
链接二 ：
立即下载
Previous
: SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection
Next
: Report of foreign issuer [Rules 13a-16 and 15d-16]
© SINOVAC All rights reserved
EN
